Understanding how a specific receptor affects immune response in Pneumocystis pneumonia.
Official title: The Role of the EphA2 Receptor Kinase Pathway in Pneumocystis Pneumonia (PCP)
Funded at Mayo Clinic Rochester · NIH-10988290 · Data updated 2026-11-12
This study is looking at how a specific protein in immune cells affects the body's response to a serious lung infection called Pneumocystis pneumonia, which often affects people with AIDS, to find new ways to help improve their immune system and reduce lung damage.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | November 16, 2023 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $195,698 |
| NIH project number | 5R21AI181542-02 |
| Project ID | NIH-10988290 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with AIDS or other immunosuppressive conditions who are at risk for Pneumocystis pneumonia.
✕Less likely to help
Patients who do not have compromised immune systems or who are not at risk for Pneumocystis pneumonia may not benefit from this research.
What this research studies
This research investigates the role of the EphA2 receptor kinase pathway in the immune response of alveolar macrophages during Pneumocystis pneumonia (PCP), a serious infection often seen in individuals with AIDS. The study aims to uncover how this receptor influences the attachment of the Pneumocystis fungus to immune cells and its subsequent effects on inflammation and lung injury. By examining the interactions between the EphA2 receptor and Pneumocystis, researchers hope to identify new therapeutic targets that could enhance the immune response in affected patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for Pneumocystis pneumonia, potentially reducing morbidity and mortality in patients with compromised immune systems.
How similar studies have gone: Previous research has shown the importance of the EphA2 receptor in immune responses, suggesting that this approach may yield valuable insights and potential breakthroughs.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Limper, Andrew H — Mayo Clinic Rochester
- Study coordinator: Limper, Andrew H
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.